• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.尿激酶型纤溶酶原激活物及其受体轴的激活对于前列腺癌小鼠模型中巨噬细胞浸润是必不可少的。
Neoplasia. 2011 Jan;13(1):23-30. doi: 10.1593/neo.10728.
2
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.RNA干扰介导的尿激酶型纤溶酶原激活剂及尿激酶型纤溶酶原激活剂受体的敲低可抑制前列腺癌细胞的侵袭、存活及体内致瘤性。
J Biol Chem. 2005 Oct 28;280(43):36529-40. doi: 10.1074/jbc.M503111200. Epub 2005 Aug 26.
3
Inactivation of uPA and its receptor uPAR by 3,3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration.3,3'-二吲哚甲烷(DIM)使尿激酶型纤溶酶原激活剂(uPA)及其受体(uPAR)失活,从而抑制前列腺癌细胞的生长和迁移。
J Cell Biochem. 2009 Jun 1;107(3):516-27. doi: 10.1002/jcb.22152.
4
Macrophage-dependent cleavage of the laminin receptor α6β1 in prostate cancer.前列腺癌细胞中依赖巨噬细胞的层粘连蛋白受体 α6β1 的裂解。
Mol Cancer Res. 2011 Oct;9(10):1319-28. doi: 10.1158/1541-7786.MCR-11-0080. Epub 2011 Aug 8.
5
Urokinase and urokinase receptor participate in regulation of neuronal migration, axon growth and branching.尿激酶和尿激酶受体参与神经元迁移、轴突生长和分支的调节。
Eur J Cell Biol. 2016 Sep;95(9):295-310. doi: 10.1016/j.ejcb.2016.05.003. Epub 2016 Jun 3.
6
Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.尿激酶型纤溶酶原激活物/尿激酶型纤溶酶原激活物受体和 maspin 在口腔鳞状细胞癌中的表达:与浸润方式和临床病理因素的关系。
Oncol Rep. 2011 Dec;26(6):1555-60. doi: 10.3892/or.2011.1419. Epub 2011 Aug 10.
7
The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.在小鼠中,尿激酶受体可独立于尿激酶型纤溶酶原激活剂促进癌症转移。
Am J Pathol. 2009 Jul;175(1):190-200. doi: 10.2353/ajpath.2009.081053. Epub 2009 Jun 4.
8
Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins.尿激酶型纤溶酶原激活物(uPA)介导的动脉粥样硬化机制:uPA 受体和 S100A8/A9 蛋白的作用。
J Biol Chem. 2011 Jun 24;286(25):22665-77. doi: 10.1074/jbc.M110.202135. Epub 2011 May 2.
9
Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis.骨肉瘤从非转移表型向转移表型的进展与自分泌和旁分泌尿激酶型纤溶酶原激活物(uPA)轴的激活存在因果关联。
PLoS One. 2015 Aug 28;10(8):e0133592. doi: 10.1371/journal.pone.0133592. eCollection 2015.
10
Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice.尿激酶型纤溶酶原激活物受体促进巨噬细胞浸润到载脂蛋白E缺陷小鼠的血管壁中。
J Cell Physiol. 2005 Jul;204(1):73-82. doi: 10.1002/jcp.20262.

引用本文的文献

1
MBs-based ultrasound molecular imaging for early diagnosis of castration-resistant prostate cancer.基于微泡的超声分子成像用于去势抵抗性前列腺癌的早期诊断。
BMC Cancer. 2025 Apr 24;25(1):769. doi: 10.1186/s12885-025-14143-7.
2
Urokinase Plasminogen Activator Receptor: An Important Focal Player in Chronic Subdural Hematoma?尿激酶型纤溶酶原激活物受体:慢性硬脑膜下血肿的重要焦点?
Inflammation. 2024 Jun;47(3):1015-1027. doi: 10.1007/s10753-023-01957-5. Epub 2024 Jan 18.
3
Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics.利用空间转录组学分析结直肠癌共识分子亚型的异质性。
NPJ Precis Oncol. 2024 Jan 10;8(1):10. doi: 10.1038/s41698-023-00488-4.
4
The Roles of Tumor-Associated Macrophages in Prostate Cancer.肿瘤相关巨噬细胞在前列腺癌中的作用
J Oncol. 2022 Sep 7;2022:8580043. doi: 10.1155/2022/8580043. eCollection 2022.
5
Role of Serine Proteases at the Tumor-Stroma Interface.丝氨酸蛋白酶在肿瘤-基质界面的作用。
Front Immunol. 2022 Feb 11;13:832418. doi: 10.3389/fimmu.2022.832418. eCollection 2022.
6
The Plasminogen-Activator Plasmin System in Physiological and Pathophysiological Angiogenesis.纤溶酶原激活物-纤溶酶系统在生理性和病理性血管生成中的作用。
Int J Mol Sci. 2021 Dec 29;23(1):337. doi: 10.3390/ijms23010337.
7
uPAR: An Essential Factor for Tumor Development.尿激酶型纤溶酶原激活物受体:肿瘤发展的关键因素
J Cancer. 2021 Oct 17;12(23):7026-7040. doi: 10.7150/jca.62281. eCollection 2021.
8
Determination of urokinase-type plasminogen activator serum levels in healthy and oncologic cats.健康猫和患癌猫血清中尿激酶型纤溶酶原激活剂水平的测定。
Can J Vet Res. 2020 Jan;84(1):60-66.
9
Tumor angiogenesis: causes, consequences, challenges and opportunities.肿瘤血管生成:原因、后果、挑战与机遇。
Cell Mol Life Sci. 2020 May;77(9):1745-1770. doi: 10.1007/s00018-019-03351-7. Epub 2019 Nov 6.
10
Estramustine Phosphate Inhibits TGF--Induced Mouse Macrophage Migration and Urokinase-Type Plasminogen Activator Production.磷酸雌莫司汀抑制 TGF--诱导的小鼠巨噬细胞迁移和尿激酶型纤溶酶原激活物的产生。
Anal Cell Pathol (Amst). 2018 Sep 2;2018:3134102. doi: 10.1155/2018/3134102. eCollection 2018.

本文引用的文献

1
Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways.Notch-1和Jagged-1的下调抑制前列腺癌细胞的生长、迁移和侵袭,并通过使Akt、mTOR和NF-κB信号通路失活诱导细胞凋亡。
J Cell Biochem. 2010 Mar 1;109(4):726-36. doi: 10.1002/jcb.22451.
2
Regulation of cell signalling by uPAR.尿激酶型纤溶酶原激活物受体(uPAR)对细胞信号的调节。
Nat Rev Mol Cell Biol. 2010 Jan;11(1):23-36. doi: 10.1038/nrm2821.
3
Urokinase plasminogen activator system as a potential target for cancer therapy.尿激酶纤溶酶原激活系统作为癌症治疗的一个潜在靶点。
Future Oncol. 2009 Nov;5(9):1487-99. doi: 10.2217/fon.09.108.
4
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation.肿瘤相关巨噬细胞(TAM)作为癌症相关炎症的主要参与者。
J Leukoc Biol. 2009 Nov;86(5):1065-73. doi: 10.1189/jlb.0609385. Epub 2009 Sep 9.
5
A novel model of bone-metastatic prostate cancer in immunocompetent mice.一种在免疫健全小鼠中建立骨转移性前列腺癌的新模型。
Prostate. 2009 Nov 1;69(15):1613-23. doi: 10.1002/pros.21010.
6
Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator.Notch1的靶向敲低抑制人前列腺癌细胞的侵袭,同时抑制基质金属蛋白酶-9和尿激酶型纤溶酶原激活剂。
Clin Cancer Res. 2009 Jan 15;15(2):452-9. doi: 10.1158/1078-0432.CCR-08-1631.
7
Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3 beta phosphorylation.fat-1基因的表达通过增强细胞凋亡和抑制糖原合成酶激酶-3β磷酸化来减少体内前列腺癌的生长。
Mol Cancer Ther. 2008 Oct;7(10):3203-11. doi: 10.1158/1535-7163.MCT-08-0494.
8
Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.前列腺癌细胞衍生的尿激酶型纤溶酶原激活剂有助于骨内肿瘤生长和骨转换。
Neoplasia. 2008 May;10(5):439-49. doi: 10.1593/neo.08106.
9
Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration.尿激酶型纤溶酶原激活剂在巨噬细胞趋化性和骨骼肌再生中发挥着重要作用。
J Immunol. 2008 Jan 15;180(2):1179-88. doi: 10.4049/jimmunol.180.2.1179.
10
Targeting uPA/uPAR in prostate cancer.靶向前列腺癌中的尿激酶型纤溶酶原激活剂/尿激酶型纤溶酶原激活剂受体
Cancer Treat Rev. 2007 Oct;33(6):521-7. doi: 10.1016/j.ctrv.2007.06.003. Epub 2007 Jul 19.

尿激酶型纤溶酶原激活物及其受体轴的激活对于前列腺癌小鼠模型中巨噬细胞浸润是必不可少的。

Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.

机构信息

Department of Internal Medicine and Urology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109-5946, USA.

出版信息

Neoplasia. 2011 Jan;13(1):23-30. doi: 10.1593/neo.10728.

DOI:10.1593/neo.10728
PMID:21245937
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3022425/
Abstract

Macrophages within the tumor microenvironment promote angiogenesis, extracellular matrix breakdown, and tumor cell migration, invasion, and metastasis. Activation of the urokinase plasminogen activator (uPA) and its receptor (uPAR) axis promotes prostate cancer tumorigenicity, invasion, metastasis, and survival within the tumor microenvironment. The link between macrophage infiltration and the uPA/uPAR axis in prostate cancer development has not been established, although it has been reported that uPA plays a critical role inmonocyte and macrophage chemotaxis. In this study, murine prostate cancer RM-1 cells were subcutaneously inoculated into wild-type (WT), uPA(-/-), and uPAR(-/-) mice. Tumor volume was significantly diminished in both uPA(-/-) and uPAR(-/-) mice compared with WT controls. Greater inhibition of tumor volume was also observed in uPA(-/-) mice compared with uPAR(-/-) mice, suggesting the important contribution of stromal-derived uPA to sustain the tumor growth. Immunohistochemical staining revealed that tumors in uPA(-/-) and uPAR(-/-) mice displayed significantly lower proliferative indices, higher apoptotic indices, and less neovascularity compared with the tumors in WT mice. Tumors in uPA(-/-) and uPAR(-/-) mice displayed significantly less macrophage infiltration as demonstrated by F4/80 staining and MAC3(+) cell numbers by flow cytometry compared with the tumors from WT mice. These findings suggest that the uPA/uPAR axis acts in both autocrine and paracrine manners in the tumor microenvironment, and activation of uPA/uPAR axis is essential for macrophage infiltration into prostate tumors.

摘要

肿瘤微环境中的巨噬细胞促进血管生成、细胞外基质降解以及肿瘤细胞迁移、浸润和转移。尿激酶纤溶酶原激活物 (uPA) 及其受体 (uPAR) 轴的激活促进了前列腺癌的肿瘤发生、浸润、转移和在肿瘤微环境中的存活。尽管已经报道 uPA 在单核细胞和巨噬细胞趋化作用中发挥关键作用,但巨噬细胞浸润与前列腺癌发展中 uPA/uPAR 轴之间的联系尚未确定。在这项研究中,将鼠前列腺癌 RM-1 细胞皮下接种到野生型 (WT)、uPA(-/-) 和 uPAR(-/-) 小鼠中。与 WT 对照组相比,uPA(-/-) 和 uPAR(-/-) 小鼠中的肿瘤体积明显减小。与 uPAR(-/-) 小鼠相比,uPA(-/-) 小鼠中的肿瘤体积抑制更为明显,这表明基质衍生的 uPA 对维持肿瘤生长具有重要贡献。免疫组织化学染色显示,与 WT 小鼠的肿瘤相比,uPA(-/-) 和 uPAR(-/-) 小鼠的肿瘤显示出更低的增殖指数、更高的凋亡指数和更少的新生血管形成。与 WT 小鼠的肿瘤相比,uPA(-/-) 和 uPAR(-/-) 小鼠的肿瘤中巨噬细胞浸润明显减少,这通过 F4/80 染色和流式细胞术检测的 MAC3(+) 细胞数量得到证实。这些发现表明,uPA/uPAR 轴在肿瘤微环境中以自分泌和旁分泌方式发挥作用,uPA/uPAR 轴的激活对于巨噬细胞浸润前列腺肿瘤是必不可少的。